5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells

References

• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653–664.
   PubMed Web of Science ®Google Scholar
• Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30:592–599.
   PubMed Web of Science ®Google Scholar
• Allen TM, Mumbengegwi DR, Charrois GJR. Anti-Cd19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res. 2005;11:3567–3573.
   PubMed Web of Science ®Google Scholar
• Pillai K, Pourgholami MH, Chua TC, et al. Muc1 as a potential target in anticancer therapies. Am J Clin Oncol. 2015;38:108–118.
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Stojanovska L, Gargosky SE. Muc1 (Cd227): a multi-tasked molecule. Cell Mol Life Sci. 2015;72:4475–4500.
   PubMed Web of Science ®Google Scholar
• Li Y, Cozzi PJ. Muc1 is a promising therapeutic target for prostate cancer therapy. Curr Cancer Drug Targets. 2007;7:259–271.
   PubMed Web of Science ®Google Scholar
• Ferreira CS, Cheung MC, Missailidis S, et al. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009;37:866–876.
   PubMed Web of Science ®Google Scholar
• Tan L, Neoh KG, Kang E-T, et al. Pegylated anti-Muc1 aptamer–doxorubicin complex for targeted drug delivery to Mcf7 breast cancer cells. Macromol Biosci. 2011;11:1331–1335.
   PubMed Web of Science ®Google Scholar
• Ray P, White RR. Aptamers for targeted drug delivery. Pharmaceuticals (Basel). 2010;3:1761.
   PubMedGoogle Scholar
• Jalalian SH, Taghdisi SM, Shahidi Hamedani N, et al. Epirubicin loaded super paramagnetic iron oxide nanoparticle–aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci. 2013;50:191–197.
   PubMed Web of Science ®Google Scholar
• Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, et al. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008;26:442–449.
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Torchilin VP, Zalipsky S. Long-circulating strerically protected liposomes. In: Torchillin VP, Weissig V, editor. Liposomes. London: Oxford University Press; 2010. p. 231–265.
   Google Scholar
• Gu F, Langer R, Farokhzad OC. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol. 2009;544:589–598.
   PubMedGoogle Scholar
• Moosavian SA, Abnous K, Badiee A, et al. Improvement in the drug delivery and anti-tumor efficacy of pegylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Colloids Surf B Biointerfaces. 2016;139:228–236.
   PubMed Web of Science ®Google Scholar
• Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466–468.
   PubMed Web of Science ®Google Scholar
• Amin M, Badiee A, Jaafari MR. Improvement of pharmacokinetic and antitumor activity of pegylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J Pharm. 2013;458:324–333.
   PubMed Web of Science ®Google Scholar
• Horowitz AT, Barenholz Y, Gabizon AA. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochimica Et Biophysica Acta (BBA) Biomembranes. 1992;1109:203–209.
   PubMed Web of Science ®Google Scholar
• Huang Z, Jaafari MR, Szoka FC Jr. Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery. Angew Chem Int Ed. 2009;48:4146–4149.
   PubMed Web of Science ®Google Scholar
• Huang Z, Szoka FC Jr. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J Am Chem Soc. 2008;130:15702–15712.
   PubMed Web of Science ®Google Scholar
• Schluep T, Hwang J, Cheng J, et al. Preclinical efficacy of the camptothecin-polymer conjugate It-101 in multiple cancer models. Clin Cancer Res. 2006;12:1606–1614.
   PubMed Web of Science ®Google Scholar
• Gupta PK, Hung CT. Quantitative evaluation of targeted drug delivery systems. Int J Pharm. 1989;56:217–226.
   Web of Science ®Google Scholar
• Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115:10938–10966.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink WE, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161:175–187.
   PubMed Web of Science ®Google Scholar
• Béduneau A, Saulnier P, Benoit J-P. Active targeting of brain tumors using nanocarriers. Biomaterials. 2007;28:4947–4967.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Kajimoto K, Hatakeyama H, et al. Advances in an active and passive targeting to tumor and adipose tissues. Expert Opin Drug Deliv. 2015;12:41–52.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 2010;197:3–53.
   PubMedGoogle Scholar
• van der Meel R, Vehmeijer LJC, Kok RJ, et al. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev. 2013;65:1284–1298.
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732–6740.
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, et al. Anti-Her2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002;8:1172–1181.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615–1626.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760.
   PubMed Web of Science ®Google Scholar
• Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine (London, England). 2013;8:1509–1528.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Biswas S, Torchilin VP. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004;64:7668–7672.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci. 2006;103:6315–6320.
   PubMed Web of Science ®Google Scholar
• Xing H, Tang L, Yang X, et al. Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo. J Mater Chem B Mater Biol Med. 2013;1:5288–5297.
   PubMed Web of Science ®Google Scholar
• Alshaer W, Hillaireau H, Vergnaud J, et al. Functionalizing liposomes with anti-Cd44 aptamer for selective targeting of cancer cells. Bioconjug Chem. 2015;26:1307–1313.
   PubMed Web of Science ®Google Scholar
• Baek SE, Lee KH, Park YS, et al. Rna aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. J Control Release. 2014;196:234–242.
   PubMed Web of Science ®Google Scholar
• Pieve CD, Perkins AC, Missailidis S. Anti-Muc1 aptamers: radiolabelling with 99mTc and biodistribution in Mcf-7 tumour-bearing mice. Nuclear Med Biol. 2009;36:703–710.
   PubMed Web of Science ®Google Scholar
• Kamps JAAM, Scherphof GL. Liposomes in biological systems. In: Torchilin VP, Weissig V, editors. Liposomes. New York: Oxford University Press; 2003. p. 271–272.
   Google Scholar
• Hong RL, Huang CJ, Tseng YL, et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res. 1999;5:3645–3652.
   PubMed Web of Science ®Google Scholar
• Fathi S, Oyelere AK. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice? Future Med Chem 2016;8:2091–2112.
   PubMed Web of Science ®Google Scholar
• Allen TM. Pharmacokinetics and biopharmaceutics of lipid-based drug formulations. In: Liposome Technology. vol. 3. NewYork: Informa Healthcare; 2007. p. 49–64.
   Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Martin SM, Ma Y, et al. Efficacy, biodistribution, and pharmacokinetics of Cd22-targeted pegylated liposomal doxorubicin in a B-Cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res. 2010;16:2760–2768.
   PubMed Web of Science ®Google Scholar